未知生产厂商
Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
Autologous peripheral blood-derived CD34+ cells have potential tissue repair ability in part due to its anti-inflammatory function which were demonstrated in pre-clinical models, including one of lung inflammation. Due to the pre-programmed tissue repair effects mediated by anti-inflammatory and pro-angiogenic functions of these cells, this cell therapy is currently being investigated against COVID-19-induced lung damage in recovered adult patients that still are experiencing hypoxia and require supplemental oxygen.
